THE BIOTECH GROWTH TRUST PLC
9 May 2013
Allotment of Ordinary Shares
THE BIOTECH GROWTH TRUST PLC (the "Company") announces the allotment of 75,000
Ordinary shares of 25p each fully paid from its block listing authority.
These shares were issued today at a price of 384.00 pence per share, which
equates to a premium to the estimated net asset value at the time of
transaction of 0.9%. The net asset value per Ordinary share at the close of
business on 8 May 2013 was 381.02 pence per share.
Following this issue, the Company has the ability to issue a further 1,570,000
Ordinary shares under its block listing facility.
Following this transaction the Company hereby notifies the market that it has
in issue 66,966,347 Ordinary shares of 25p each all with voting rights. No
shares were held in treasury at the date of announcement.
The figure of 66,966,347 may be used by shareholders as the denominator for the
calculation by which they may determine if they are required to notify their
interest in, or change to their interest in, the Company under the FSA's
Disclosure and Transparency Rules.
Enquiries:
Mark Pope
Frostrow Capital LLP
Tel: 020 3 008 4913
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.